FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992217485> ?p ?o ?g. }

• W2992217485 endingPage "e1916598" @default.
• W2992217485 startingPage "e1916598" @default.
• W2992217485 abstract "β-Blockers are prescribed to most patients with heart failure (HF) with a preserved ejection fraction (HFpEF), but their effect on HFpEF remains unclear.To determine the association of β-blocker use with HF hospitalizations and cardiovascular disease (CVD) mortality, overall and in strata of patients with an ejection fraction (EF) of 50% or greater or less than 50%.For 1761 participants from North and South America enrolled in the multicenter, double-blinded Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist randomized clinical trial of spironolactone for patients with HFpEF between August 10, 2006, and January 31, 2012, the association of baseline β-blocker use with HF hospitalization and CVD mortality was analyzed using unadjusted and adjusted Cox proportional hazards regression models, overall and in strata of patients with an EF of 50% or greater or less than 50%. Participants had symptomatic HF with a left ventricular EF of 45% or greater, with enrollment based on either hospitalization attributed to decompensated HF in the prior year or elevated natriuretic peptide levels. Statistical analysis was performed from January 31 to May 2, 2019.Use of β-blockers.Incident HF hospitalization and CVD mortality.Among 1761 participants included in the analysis (879 women and 882 men; mean [SD] age, 71.5 [9.6] years), 1394 (79.2%) reported β-blocker use and 1567 (89.0%) had an EF of 50% or greater. Hospitalizations for HF occurred for 399 participants (22.7%), and CVD mortality occurred for 229 participants (13.0%). Use of β-blockers was associated with a higher risk of HF hospitalization among patients with HFpEF with an EF of 50% or greater (hazard ratio, 1.74 [95% CI, 1.28-2.37]; P < .001) but not among patients with an EF between 45% and 49% (hazard ratio, 0.68 [95% CI, 0.28-1.63]; P = .39). There was a significant interaction between β-blocker use and EF threshold for incident HF hospitalizations (P = .03). Use of β-blockers was not associated with a change in CVD mortality.For patients with an EF of 50% or greater, β-blocker use was associated with an increased risk of HF hospitalizations but not CVD mortality. For patients with an EF between 45% and 49%, there was no such association." @default.
• W2992217485 created "2019-12-13" @default.
• W2992217485 creator A5000492757 @default.
• W2992217485 creator A5001743370 @default.
• W2992217485 creator A5009322495 @default.
• W2992217485 creator A5039267010 @default.
• W2992217485 creator A5056254705 @default.
• W2992217485 creator A5062357943 @default.
• W2992217485 creator A5087729983 @default.
• W2992217485 date "2019-12-04" @default.
• W2992217485 modified "2023-10-14" @default.
• W2992217485 title "Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction" @default.
• W2992217485 cites W1811184201 @default.
• W2992217485 cites W1990780376 @default.
• W2992217485 cites W2016296553 @default.
• W2992217485 cites W2040737873 @default.
• W2992217485 cites W2041601376 @default.
• W2992217485 cites W2048229190 @default.
• W2992217485 cites W2065257276 @default.
• W2992217485 cites W2068519950 @default.
• W2992217485 cites W2088759164 @default.
• W2992217485 cites W2104209472 @default.
• W2992217485 cites W2108790161 @default.
• W2992217485 cites W2110392728 @default.
• W2992217485 cites W2114369401 @default.
• W2992217485 cites W2127254785 @default.
• W2992217485 cites W2129967926 @default.
• W2992217485 cites W2133217116 @default.
• W2992217485 cites W2146924385 @default.
• W2992217485 cites W21478844 @default.
• W2992217485 cites W2152072062 @default.
• W2992217485 cites W2161444540 @default.
• W2992217485 cites W2166504467 @default.
• W2992217485 cites W2167760816 @default.
• W2992217485 cites W2170131723 @default.
• W2992217485 cites W2171580996 @default.
• W2992217485 cites W2178738676 @default.
• W2992217485 cites W2187526770 @default.
• W2992217485 cites W2213926659 @default.
• W2992217485 cites W2296998040 @default.
• W2992217485 cites W2326508838 @default.
• W2992217485 cites W2340731691 @default.
• W2992217485 cites W2401139688 @default.
• W2992217485 cites W2427094903 @default.
• W2992217485 cites W2475261460 @default.
• W2992217485 cites W2609231773 @default.
• W2992217485 cites W2758197294 @default.
• W2992217485 cites W2761111693 @default.
• W2992217485 cites W2790275265 @default.
• W2992217485 cites W2790353319 @default.
• W2992217485 cites W2842271423 @default.
• W2992217485 cites W2887418966 @default.
• W2992217485 cites W2888326854 @default.
• W2992217485 cites W2899617144 @default.
• W2992217485 cites W2899687631 @default.
• W2992217485 cites W2964436936 @default.
• W2992217485 cites W2967290218 @default.
• W2992217485 cites W3023522280 @default.
• W2992217485 cites W4240616498 @default.
• W2992217485 cites W4241612172 @default.
• W2992217485 cites W4293084779 @default.
• W2992217485 cites W4293860347 @default.
• W2992217485 cites W52877415 @default.
• W2992217485 doi "https://doi.org/10.1001/jamanetworkopen.2019.16598" @default.
• W2992217485 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6902757" @default.
• W2992217485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31800067" @default.
• W2992217485 hasPublicationYear "2019" @default.
• W2992217485 type Work @default.
• W2992217485 sameAs 2992217485 @default.
• W2992217485 citedByCount "78" @default.
• W2992217485 countsByYear W29922174852020 @default.
• W2992217485 countsByYear W29922174852021 @default.
• W2992217485 countsByYear W29922174852022 @default.
• W2992217485 countsByYear W29922174852023 @default.
• W2992217485 crossrefType "journal-article" @default.
• W2992217485 hasAuthorship W2992217485A5000492757 @default.
• W2992217485 hasAuthorship W2992217485A5001743370 @default.
• W2992217485 hasAuthorship W2992217485A5009322495 @default.
• W2992217485 hasAuthorship W2992217485A5039267010 @default.
• W2992217485 hasAuthorship W2992217485A5056254705 @default.
• W2992217485 hasAuthorship W2992217485A5062357943 @default.
• W2992217485 hasAuthorship W2992217485A5087729983 @default.
• W2992217485 hasBestOaLocation W29922174851 @default.
• W2992217485 hasConcept C126322002 @default.
• W2992217485 hasConcept C164705383 @default.
• W2992217485 hasConcept C2776379505 @default.
• W2992217485 hasConcept C2777099384 @default.
• W2992217485 hasConcept C2778198053 @default.
• W2992217485 hasConcept C2778742482 @default.
• W2992217485 hasConcept C50382708 @default.
• W2992217485 hasConcept C71924100 @default.
• W2992217485 hasConcept C78085059 @default.
• W2992217485 hasConceptScore W2992217485C126322002 @default.
• W2992217485 hasConceptScore W2992217485C164705383 @default.
• W2992217485 hasConceptScore W2992217485C2776379505 @default.
• W2992217485 hasConceptScore W2992217485C2777099384 @default.
• W2992217485 hasConceptScore W2992217485C2778198053 @default.
• W2992217485 hasConceptScore W2992217485C2778742482 @default.

• next